A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD
Status:
Terminated
Trial end date:
2020-04-24
Target enrollment:
Participant gender:
Summary
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose
study that will investigate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets)
- a sublingual formulation of cyclobenzaprine. Following successful screening and
randomization, eligible patients will have a telephonic visit at week 2 and then return
regularly to the study clinic for monthly visits for assessments of efficacy and safety.